GeneDx Holdings Corp.
WGS
$70.69
-$4.81-6.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 24.51% | 46.64% | 43.76% | 40.35% | 70.60% |
| Total Other Revenue | 156.44% | 691.91% | 166.88% | 2.88% | -34.48% |
| Total Revenue | 26.50% | 51.86% | 45.63% | 39.56% | 66.57% |
| Cost of Revenue | 24.74% | 10.94% | 15.34% | 14.73% | 10.39% |
| Gross Profit | 27.29% | 76.71% | 65.07% | 56.11% | 115.27% |
| SG&A Expenses | 58.39% | 54.63% | 9.93% | 27.71% | 17.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.11% | 41.76% | 15.59% | 20.56% | 15.18% |
| Operating Income | -245.70% | 58.18% | 184.70% | 66.57% | 149.00% |
| Income Before Tax | -436.72% | 11.62% | 135.97% | 70.07% | 120.68% |
| Income Tax Expenses | -2,250.00% | 625.53% | -29.47% | 645.12% | 94.16% |
| Earnings from Continuing Operations | -424.86% | 8.14% | 137.05% | 67.74% | 121.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -424.86% | 8.14% | 137.05% | 67.74% | 121.10% |
| EBIT | -245.70% | 58.18% | 184.70% | 66.57% | 149.00% |
| EBITDA | -150.87% | 274.69% | 382.62% | 113.47% | 266.65% |
| EPS Basic | -410.73% | 13.59% | 134.51% | 70.13% | 119.68% |
| Normalized Basic EPS | -183.55% | 44.94% | 136.36% | 72.23% | 197.73% |
| EPS Diluted | -410.73% | 13.59% | 132.73% | 70.13% | 119.68% |
| Normalized Diluted EPS | -183.55% | 44.94% | 134.92% | 72.23% | 197.73% |
| Average Basic Shares Outstanding | 4.56% | 6.28% | 7.37% | 8.00% | 7.20% |
| Average Diluted Shares Outstanding | 4.56% | 6.28% | 11.78% | 8.00% | 7.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |